Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas

Purpose: Clinically aggressive meningiomas (MGMs) are rare but treatment-resistant tumors in need for more effective therapies. Because tumor-infiltrating T lymphocytes (TILs) are essential for successful immunotherapy, we assessed TIL numbers and their activation status in primary (p-) and recurrent (r-) meningiomas and their impact on survival. Experimental Design: Presence of TILs was analyzed in 202 clinically well-annotated cases (n = 123 pMGMs and n = 79 rMGMs) focusing on higher-grade meningiomas [n = 97 World Health Organization (WHO) °II, n = 62 WHO°III]. TILs were quantified by a semiautomated analysis on whole-tissue sections stained by multicolor immunofluorescence for CD3, CD8, FOXP3, and programmed cell death protein 1 (PD-1). Results: Median T-cell infiltration accounted for 0.59% TILs per total cell count. Although there were no significant WHO°-dependent changes regarding helper (CD3+CD8−FOXP3−) and cytotoxic (CD3+CD8+FOXP3−) TILs in pMGMs, higher number of cytotoxic TILs were associated with an improved progression-free survival (PFS) independent of prognostic confounders. rMGMs were characterized by lower numbers of TILs in general, helper, and cytotoxic TILs. The additional analysis of their activation status revealed that a proportion of PD-1+CD8+ TILs within the TIL population was significantly decreased with higher WHO grade and in rMGMs. Furthermore, lower proportions of PD-1+CD8+ TILs were associated with inferior PFS in multivariate analyses, arguing for PD-1 as activation rather than exhaustion marker. Conclusions: We identified higher numbers of CD3+CD8+FOXP3− TILs and proportions of PD-1–expressing CD3+CD8+FOXP3− TILs as novel biomarkers for better survival. These findings might facilitate the selection of patients who may benefit from immunotherapy and argue in favor of an intervention in primary rather than recurrent tumors.

[1]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. , 2018, Neuro-oncology.

[2]  M. Weller,et al.  Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence , 2018, Acta Neuropathologica.

[3]  Jan Poleszczuk,et al.  In Silico Modeling of Immunotherapy and Stroma-Targeting Therapies in Human Colorectal Cancer. , 2017, Cancer research.

[4]  A. Warth,et al.  Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer , 2017, Oncoimmunology.

[5]  N. Labarrière,et al.  PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy? , 2017, Oncoimmunology.

[6]  V. Prasad,et al.  Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. , 2017, Seminars in oncology.

[7]  R. Beroukhim,et al.  Genomic landscape of high-grade meningiomas , 2017, Journal of Neurological Surgery Part B: Skull Base.

[8]  R. Geisberger,et al.  T cell exhaustion: from pathophysiological basics to tumor immunotherapy , 2017, Cell Communication and Signaling.

[9]  J. Lunceford,et al.  Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[11]  K. Aldape,et al.  TERT Promoter Mutations and Risk of Recurrence in Meningioma. , 2016, Journal of the National Cancer Institute.

[12]  N. Grabe,et al.  Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade , 2016, Oncotarget.

[13]  E. Buchbinder,et al.  CTLA-4 and PD-1 Pathways , 2016, American journal of clinical oncology.

[14]  M. Berger,et al.  Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma , 2015, Journal of Neuro-Oncology.

[15]  B. Dréno,et al.  PD-1 expression conditions T cell avidity within an antigen-specific repertoire , 2015, Oncoimmunology.

[16]  E. Wherry,et al.  Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.

[17]  Daniel E. Speiser,et al.  Inhibitory Receptors Beyond T Cell Exhaustion , 2015, Front. Immunol..

[18]  R. Herbst,et al.  Objective measurement and clinical significance of TILs in non-small cell lung cancer. , 2015, Journal of the National Cancer Institute.

[19]  Anne E Carpenter,et al.  Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma , 2014, Oncotarget.

[20]  J. Wolchok,et al.  Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Lin Qiu,et al.  Relationships between tumor microenvironment and clinicopathological parameters in meningioma. , 2014, International journal of clinical and experimental pathology.

[22]  D. Douek,et al.  PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. , 2014, The Journal of clinical investigation.

[23]  J. Nault,et al.  High Incidence of Activating TERT Promoter Mutations in Meningiomas Undergoing Malignant Progression , 2014, Brain pathology.

[24]  G. Zada,et al.  Recent developments in chemotherapy for meningiomas: a review. , 2013, Neurosurgical focus.

[25]  J. Bruce,et al.  The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. , 2013, Neuro-oncology.

[26]  Shaohua Chen,et al.  The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies , 2013, Journal of Hematology & Oncology.

[27]  B. Nahed,et al.  Radiation Treatment for WHO Grade II and III Meningiomas , 2013, Front. Oncol..

[28]  G. Freeman,et al.  Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. , 2013, Cancer research.

[29]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[30]  A. Órfão,et al.  Immunophenotypic identification and characterization of tumor cells and infiltrating cell populations in meningiomas. , 2012, The American journal of pathology.

[31]  J. Plate.  Advances in therapeutic vaccines for pancreatic cancer. , 2012, Discover medicine.

[32]  C. Meyer,et al.  The three main stumbling blocks for anticancer T cells. , 2012, Trends in immunology.

[33]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[34]  D. Yin,et al.  CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes , 2011, Breast Cancer Research and Treatment.

[35]  A. Unterberg,et al.  Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF-β , 2011, Clinical Cancer Research.

[36]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[37]  S. Rosenberg,et al.  Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells , 2010, Journal of immunotherapy.

[38]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[39]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[40]  David E. Anderson,et al.  Preferential In Situ CD4+CD56+ T Cell Activation and Expansion within Human Glioblastoma , 2008, The Journal of Immunology.

[41]  Arie Perry,et al.  Histological classification and molecular genetics of meningiomas , 2006, The Lancet Neurology.

[42]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[43]  H. Zou,et al.  Regularization and variable selection via the elastic net , 2005 .

[44]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[45]  M. Esiri,et al.  Immunocytochemical study of the cellular immune response in meningiomas. , 1988, Journal of clinical pathology.

[46]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. , 2019, Neuro-oncology.

[47]  M. Kloor,et al.  The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. , 2009, Cancer immunity.

[48]  B. Scheithauer,et al.  "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. , 1999, Cancer.